Association of miR‑100 expression with clinicopathological features and prognosis of patients with lung cancer
- Xiaolong Ma
- Jiaqi Zhou
- Hongyan Mo
- Ying Ying
Published online on: May 22, 2019
Copyright: © Ma et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
| PMC Statistics:
Total PDF Downloads:
| PMC Statistics:
The expression of microRNA (miR)‑100 in non‑small cell lung cancer (NSCLC) and its association with clinicopathological features and poor prognosis were investigated. A total of 283 patients with NSCLC were enrolled in The First Hospital of Jiaxing from February 2013 to April 2015. Total RNA was extracted from cancer tissues and corresponding adjacent normal tissues. The expression of miR‑100 was detected by RT‑qPCR. Association between the expression level of miR‑100 with clinicopathological features and prognosis of NSCLC were analyzed. The expression level of miR‑100 in NSCLC tissues was lower than that in the normal tissues (P<0.05). According to the median expression level of miR‑100 in cancer tissue, patients were divided into the high expression and low expression groups. Cross‑tabulation analysis showed that the expression level of miR‑100 was significantly associated with patients' age, TNM stage, metastasis and histological type (P<0.05), but not with sex (P>0.05). The proportion of patients with low miR‑100 expression was higher in patients who died than in those who survived (P<0.05). Univariate prognostic analysis showed that miR‑100 expression, age, TNM staging, and metastasis may be risk factors for poor prognosis in patients with NSCLC. Cox multivariate regression analysis showed that the downregulated miR‑100 expression, advanced TNM stage, and metastasis were independent risk factors for poor prognosis of NSCLC. The relatively low expression level of miR‑100 in NSCLC is associated with poor prognosis of patients. Therefore, miR‑100 shows potential as a prognostic marker for NSCLC.